MedTrace Logo

Glutamine PET Imaging Colorectal Cancer

NCT03275974 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-01-02

No results posted yet for this study

Summary

The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.

Conditions

  • RAS Wild Type
  • Stage IV Colorectal Cancer
  • Stage IVA Colorectal Cancer
  • Stage IVB Colorectal Cancer

Interventions

BIOLOGICAL

Carbon C 11 Glutamine

Given by IV

BIOLOGICAL

Fluorine F 18 L-glutamate Derivative BAY94-9392

Given by IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

PROCEDURE

Blood Draw

Undergo venous blood draws

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Simone Krebs · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2025-12-23
Completion
2025-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275974 on ClinicalTrials.gov